ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Non-Small-Cell Lung Carcinoma
Neoplasm Metastasis
Ovarian Cancer
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer

Breast Cancer trials near Cleveland, OH, USA:

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC)

Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...

Enrolling
Breast Cancer
Breast Neoplasm
Drug: Cyclophosphamide
Drug: Interferon infiltration of the inoculation site

Phase 3

BriaCell Therapeutics

Cleveland, Ohio, United States and 76 other locations

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy \[paclitaxel\] and a ...

Active, not recruiting
Breast Cancer Metastatic
Drug: Avelumab
Drug: Paclitaxel

Phase 2

Oncolytics Biotech

Cleveland, Ohio, United States and 17 other locations

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer....

Enrolling
Metastatic Hormone Receptor Positive Breast Cancer
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
Drug: 68Ga-R11228
Drug: 177Lu-R11228

Phase 1

Radionetics Oncology

Cleveland, Ohio, United States and 6 other locations

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specif ...

Active, not recruiting
Triple-negative Breast Cancer
Biological: Pembrolizumab
Biological: AE37 Peptide vaccine

Phase 2

NuGenerex Immuno-Oncology

Cleveland, Ohio, United States and 5 other locations

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

(Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at RD in the selected population(s) of breast...

Active, not recruiting
Breast Cancer
Drug: BB-1701

Phase 2

Eisai
Eisai

Cleveland, Ohio, United States and 48 other locations

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of...

Active, not recruiting
Breast Cancer
Drug: Eribulin
Drug: Vinorelbine

Phase 3

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 166 other locations

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)

with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determine...

Enrolling
HER2-negative Breast Cancer
Drug: Doxorubicin
Drug: Cyclophosphamide

Phase 2

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Cleveland, Ohio, United States and 42 other locations

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unre ...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab deruxtecan (T-DXd)
Drug: Ado-trastuzumab emtansine (T-DM1)

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Cleveland, Ohio, United States and 163 other locations

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-...

Active, not recruiting
Metastatic Breast Cancer
Drug: Paclitaxel
Drug: Nab-paclitaxel

Phase 3

DualityBio

Akron, Ohio, United States and 260 other locations

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)

endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast...

Enrolling
Breast Cancer
Drug: Elacestrant
Drug: Tamoxifen

Phase 3

Stemline Therapeutics
Stemline Therapeutics

Cleveland, Ohio, United States and 523 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems